Anti-TRIF/TICAM1 Antibody Picoband® 31.0647 Vervoeging

TICAM (TIR DOMAIN-CONTAINING ADAPTOR MOLECULE 1), also known as TICAM1 or TRIF, is an adapter in responding to activation of toll-like receptors (TLRs) . It mediates the rather delayed cascade of two TLR-associated signaling cascades, where the other one is dependent upon a MyD88 adapter. By genomic sequence analysis, Oshiumi et al. (2003) mapped the TICAM1 gene to chromosome 19p13.3. By coimmunoprecipitation analysis, Oshiumi et al. (2003) showed that TICAM1 interacts specifically with TLR3, but not with other TLRs. Functional analysis showed that the association of TLR3 and TICAM1 mediates dsRNA activation of IFNB, through either NFKB, AP1, or IRF3. TICAM1 activation of NFKB was found to occur predominantly through IRAK1 rather than IRAK2. Small interfering (si) RNA blockage of TICAM1, just upstream of the TIR domain, reduced IFNB production in response to dsRNA.

TIR domain-containing adapter molecule 1; TICAM-1; Proline-rich, vinculin and TIR domain-containing protein B; Putative NF-kappa-B-activating protein 502H; Toll-interleukin-1 receptor domain-containing adapter protein inducing interferon beta; MyD88-3; TIR domain-containing adapter protein inducing IFN-beta; TICAM1; PRVTIRB, TRIF

TICAM1

148022

Q8IUC6

Human

No cross-reactivity with other proteins

A synthetic peptide corresponding to a sequence at the C-terminus of human TRIF.

Ubiquitously expressed but with higher levels in liver. .

Flow Cytometry

Cytokines, Immunology, Innate Immunity, Interferons, TLR Signaling

Immunogen affinity purified.

Liquid

Involved in innate immunity against invading pathogens. Adapter used by TLR3 and TLR4 (through TICAM2) to mediate NF- kappa-B and interferon-regulatory factor (IRF) activation, and to induce apoptosis. Ligand binding to these receptors results in TRIF recruitment through its TIR domain. Distinct protein- interaction motifs allow recruitment of the effector proteins TBK1, TRAF6 and RIPK1, which in turn, lead to the activation of transcription factors IRF3 and IRF7, NF-kappa-B and FADD respectively. .

1. Carty, M., Goodbody, R., Schroder, M., Stack, J., Moynagh, P. N., Bowie, A. G.The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling.Nature Immun. 7: 1074-1081, 2006. 2. Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T., Seya, T.TICAM-I, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction.Nature Immun. 4: 161-167, 2003. 3. Yamamoto, M., Sato, S., Mori, K., Hoshino, K., Takeuchi, O., Takeda, K., Akira, S.Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling.J. Immun. 169: 6668-6672, 2002.

At -20 ̊C for one year from date of receipt. Avoid repeated freezing and thawing. Protect from light.

76422 MW

No cross reactivity with other proteins.

6

TIR domain-containing adapter molecule 1

Cytoplasmic vesicle, autophagosome . Colocalizes with UBQLN1 in the autophagosome. .

Contains 1 TIR domain.

TIR domain-containing adapter molecule 1

Rabbit IgG

Each vial contains 50% glycerol, 0.9% NaCl, 0.2% Na2HPO4, 0.02% NaN3.